Rabies Vaccine Use Up 33%, HRIG Up 76% in 2026

For biotech and pharmaceutical supply chain decision-makers, the CDC's latest advisory is a demand signal disguised as a public health notice: rabies vaccine use is up 33% and human rabies immune globulin up 76% in 2026, driven by wildlife exposure clusters including the North Carolina petting zoo incident. Manufacturers and distributors should evaluate production capacity, cold-chain logistics, and regional allocation in a market where PEP is the only effective intervention and HRIG has historically faced supply constraints.

On September 10, 2026, the Centers for Disease Control and Prevention issued a nationwide health alert warning of a measurable rise in rabies exposure incidents across the United States. The advisory, distributed through public health channels and reported by iHeartMedia news stations on September 11, cites a 17% increase in rabies-related inquiries from July through August compared with the same period in 2025. The CDC is urging the public to avoid contact with wildlife and sick animals, to wash wounds immediately with soap and water after any bite or scratch, and to seek medical evaluation without delay. Rabies remains rare in the United States, but it is almost universally fatal once clinical symptoms emerge. The alert underscores a persistent public health paradox: rabies is nearly 100% preventable with prompt post-exposure prophylaxis, yet every year thousands of people require intervention after exposure to infected wildlife or unvaccinated domestic animals.

“

This year, the agency reports that utilization of rabies vaccine has risen 33%, while use of human rabies immune globulin has climbed 76%.

The advisory's clinical centerpiece is post-exposure prophylaxis, or PEP, which combines a series of rabies vaccine doses with human rabies immune globulin. The CDC notes that PEP is nearly 100% effective when administered promptly after exposure. This year, the agency reports that utilization of rabies vaccine has risen 33%, while use of human rabies immune globulin has climbed 76%. Those two figures represent more than broader public awareness: they suggest a genuine increase in exposure events requiring medical intervention. Because HRIG is expensive, produced by a limited number of manufacturers, and subject to cold-chain constraints, a 76% utilization spike carries operational and supply chain consequences for hospitals, urgent care centers, and public health clinics. The mismatch between vaccine and immune globulin growth rates may reflect differences in clinical presentation, dosing weight, or supply availability, but it also warrants monitoring by health systems preparing for continued demand.

The alert follows several high-profile rabies exposure clusters, most notably an incident in North Carolina where three baby goats at a petting zoo tested positive for rabies after being bitten by a rabid skunk, according to NBC News. The exposure potentially affected hundreds of visitors, and health officials recommended rabies shots for more than 260 individuals who came into contact with the animals. The North Carolina event illustrates how wildlife rabies can spill into the human environment through domesticated or captive animals, amplifying the scale of exposure rapidly. Additional rabies cases have been reported in Virginia, Louisiana, and New York, indicating that the rise in inquiries is not attributable to a single geographic cluster. Together, these scattered cases reflect the underlying wildlife reservoir ecology of rabies in the United States, where raccoons, skunks, bats, and foxes remain the primary carriers.